OverviewChartNewsTraderScreen

UC DIS.CERT. 09/24 BRM/  DE000HD1NM36  /

gettex
6/7/2024  9:45:22 PM Chg.+0.530 Bid9:53:26 PM Ask9:53:26 PM Underlying Strike price Expiration date Option type
35.080EUR +1.53% 35.110
Bid Size: 1,000		 35.120
Ask Size: 1,000		 BRISTOL-MYERS SQUIBB... - - 9/27/2024 Call
GlobeNewswire 5/31 Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting P...
GlobeNewswire 5/30 Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire 5/24 Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
GlobeNewswire 5/23 Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire 5/23 Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Pr...
GlobeNewswire 5/22 CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire 5/22 Anavex Life Sciences Announces Expansion of Leadership Team
GlobeNewswire 5/16 CytomX Therapeutics Announces New Employment Inducement Grants
GlobeNewswire 5/15 Lantheus Announces Executive Appointments to Accelerate Innovation
GlobeNewswire 5/14 Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Healthcare-Industry Executive, Dav...
GlobeNewswire 5/14 Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire 5/13 Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 5/8 CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 5/8 Immunocore reports first quarter financial results and provides a business update
GlobeNewswire 5/7 CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire 5/2 Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., ...
GlobeNewswire 5/1 Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
GlobeNewswire 5/1 CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire 4/30 Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
GlobeNewswire 4/30 CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical D...
GlobeNewswire 4/25 International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on A...
GlobeNewswire 4/25 Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract ...
GlobeNewswire 4/25 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...
GlobeNewswire 4/22 ArriVent Appoints Kristine Peterson to its Board of Directors
GlobeNewswire 4/8 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Sq...